HTRS 2025 Scientific Symposium

ANCILLARY EVENTS

If you did not pre-register, you may still be able to attend on a first-come, first served basis.

HTRS PRE-CONFERENCE EDUCATION

HTRS Trainee Workshop

HTRS is now accepting applications from trainees (medical residents and fellows) who wish to attend the HTRS Trainee Workshop: Spring 2025 meeting on March 11-12, 2025, at the Loews Coronado Bay Resort. This Workshop is open to 30 MDs or DOs interested in building careers in hemostasis and/or thrombosis in either pediatric or adult medicine.

HTRS Research Colloquium

Junior faculty and early-stage investigators (MDs, DOs, PhDs and MD/PhDs) are encouraged to apply to attend the HTRS 2025 Research Colloquium on March 11-12, 2025, at the Loews Coronado Bay Resort. Interested participants must submit an application via the separate portal listed below. The Colloquium is open to 30 MDs, PhDs, or DOs interested in further career development and support for their research careers in hemostasis and/or thrombosis.

FWGBD PRE-CONFERENCE COLLOQUIUM AT HTRS 2025

The Foundation for Women and Girls with Blood Disorders (FWGBD - www.fwgbd.org​) is pleased to announce the 2025 national colloquium on uterine hemostasis. The Uterine Hemostasis Colloquium V will convene on the morning of Thursday, March 13th, 2025 (preceding the HTRS Scientific Symposium at the Loews Coronado Bay Resort), where leading faculty, researchers, and clinicians will review the state of the science with respect to the management of placenta accreta, hematological disease of newborn, fetal and neonatal alloimmune thrombocytopenia, and fetal/neonatal hemostasis and thrombosis.

Uterine Hemostasis Colloquium V: Hemostatic Disorders in Women & Girls

Registration: $75

Included: CME/CEs (~3 hours), breakfast, access to recorded presentations

Schedule & Learning Objectives

HTRS | FWGBD SICKLE CELL DISEASE RESEARCH ROUNDTABLE 

Sickle cell disease (SCD) is the most prevalent inherited hemoglobinopathy, affecting millions worldwide, particularly those of African and Asian descent. While SCD primarily impacts the hematologic system, the risk of thrombosis and thrombo-inflammation is an urgent concern within this patient population. Individuals with SCD face a significantly higher risk of developing blood clots, with an incidence of large-vessel thrombosis exceeding 12% before the age of 40. These complications contribute to severe conditions such as venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and vaso-occlusive events (VOE), commonly referred to as sickle cell crises.

Thursday, March 13, 2025

11:00 AM - 1:00 PM PT

Supported by Vertex

This roundtable luncheon, supported by Vertex, will convene leading experts, researchers, and clinicians to explore the intricate relationship between SCD and thrombosis. Attendees will gain critical insights into:

• "Reproductive Health Issues in Women with Sickle Cell Disease" , Alecia Nero, MD, MSCS, FACP
• "Anti-Adhesion and Antithrombotic Therapies in Sickle Cell Disease", Tomasz W. Kaminski, PhD
• "Basic Science and Translational Hot Topics in Sickle Cell Disease", Erica Sparkenbaugh, PhD 

Join this important conversation to help drive progress in understanding and addressing thrombosis in SCD. Stay informed, contribute to the dialogue, and support efforts to improve patient care.

HTRS 2025 AWARDS DINNER 

Event Date/Time: Friday, March 14, 2025 from 8:30 PM – 11:30 PM

Location: Flagship Cruise, California Spirit

Experience the HTRS Awards Dinner aboard the California Spirit and cruise around beautiful Coronado Bay. This event offers a perfect blend of networking, celebration, and entertainment in a picturesque setting. Open to ticketed registrants and employees of the sponsoring company, this high-profile evening is a highlight of HTRS 2025.

The evening includes:

• Cocktail reception
• Live entertainment
• Cocktail hour with appetizers (including two drink tickets)
• Buffet dinner
• HTRS Awards Program
• Live Band Karaoke – a first at HTRS!

Immerse yourself in the stunning views of Coronado Bay and the San Diego skyline as you cruise along the water. Enjoy the ocean breeze, panoramic vistas, and sparkling city lights while celebrating HTRS and our award recipients. This enchanting setting provides the perfect backdrop for an unforgettable evening!

NEW Live Band Karaoke: Get ready to take center stage with Live Band Karaoke, a first at HTRS, where you can showcase your hidden talents! This emceed event features live musicians who will back you up as you perform your favorite songs. Whether you're a seasoned performer or a first-time singer, this interactive and engaging experience promises fun and excitement for everyone. Sing your heart out and enjoy a night full of music, laughter, and camaraderie.

Other Events / Activities

• Puppy Yoga | Sponsored by Sanofi (March 13, 9:00 AM – Avalon Room): Pre-registration required. Event is limited to 50 participants.
• First-Time Attendee Welcome Session (March 13, 10:30 AM – Commodore C-E): Meet fellow first-time attendees and HTRS leaders.
• Best of HTRS 2025: "Meet Our Awardees" | Sponsored by Genentech (March 13, 7:30 PM – Avalon Room): Speed networking event, pre-registration required, limited number of participants.
• Welcome Reception (March 13, 6:00 PM – Pavilion Exhibit Tent): Kick off the conference with cocktails, appetizers, and networking.

• Closing Networking Reception (March 15, 12:40 PM – Pavilion Exhibit Tent): Wrap up the conference with a final networking session.
• Daily Exhibit Tent Scavenger Hunts: Forms for each day will be posted in the Mobile App and QR Codes will be available on signage in the Exhibit Tent. Prizes will be awarded at the Closing Reception on March 15.

SATELLITE SYMPOSIA

Open to all full-conference attendees. Meals are provided. If you did not pre-register, you may still be able to attend on a first-come, first served basis.

Select events provide Continuing Medical Education (CME) credits through the sponsor's provider. Sessions with an exclusive timeslot or offering CME are open to all full-conference attendees, including full-conference industry participants.

March 13, 2025

11:30 AM - 1:00 PM - Riding the wave – Evolving approaches to an broad treatment landscape in hemophilia

Sponsored by Sanofi

Join Dr. Sanjay Ahuja and a multidisciplinary panel as they dive into the latest advancements in hemophilia treatment. Discover firsthand how comprehensive care is evolving to meet new challenges and elevate treatment goals.

Elevate Your Hemophilia Practice: Join Our Multidisciplinary Panel Discussion

Overview and Objectives

Join us for a dynamic presentation and panel discussion to advanced hemophilia care practices. Our expert panel will explore:

• The evolving hemophilia treatment landscape.
• Expanding care goals beyond bleed management to include quality of life.
• The potential impact of new and emerging therapies on comprehensive care and patient conversations.

Session Highlights

• Current and Emerging Therapies: Understand the latest treatment approaches.
• Comprehensive Care Goals: Focus on patient-specific factors like pain, activity, and quality of life.
• Underserved Populations: Address the needs of women, the aging population, and those with comorbidities.
• Mental Health: Learn about the psychological impact of hemophilia and the role of mental health professionals.
• Patient and Caregiver Attitudes: Discuss how treatment advancements influence decisions.

Speaker: Dr. Sanjay Ahuja

8:30 PM - 10:00 PM- HYMPAVZI (marstacimab-hncq) Clinical Trial Results and Real-World Patient Experience

Sponsored by Pfizer 

• Dr. Maissaa Janbain, Tulane University School of Medicine (Maissaa Janbain, MD | Tulane School of Medicine​)
• Dr. Akshat Jain, Loma Linda University Health (Akshat Jain, MD, MPH | Loma Linda University Health​)

March 14, 2025

7:00 AM - 8:00 AM - Real-World Management of Hemophilia A & B Across Life Stages

Sponsored by Sanofi



Join us for an interactive exploration of hemophilia A and B case presentations, presented by expert speakers. Through rotating poster-style presentations we will explore real-world cases of success navigating changing life phases and patient priorities.

Speakers: Doris Quon, MD, PhD, Vanessa Salinas, MD, Candace DeBerry, ARNP-C, Maissaa Janbain, MD

7:00 AM - 8:00 AM - Complications and challenges associated with hemophilia and a rebalancing approach with HYMPAVZI (marstacimab-hncq)

Sponsored by Pfizer

• Dr. Robert Sidonio, Emory University School of Medicine (Robert F. Sidonio Jr., MD, MSc | Emory School of Medicine​)

12:30 PM - 2:00 PM - A Legacy in the Making: Experts Discuss Long-Term Outcomes and Clinical Impact of a Subcutaneous Prophylaxis Treatment in Hemophilia A 

Sponsored by Genentech

Please join us for a thought-provoking discussion between experts Maya Bloomberg and Lynn Malec as they share their perspectives on the evolution of hemophilia A management and the impact of a subcutaneous prophylaxis treatment with over a decade of clinical trial experience. The presentation will include pivotal efficacy and safety data, long-term data, and a discussion on experts' clinical practice experience. Please bring your questions to have them answered live by experts in the Q&A following the program.

Speaker: Lynn Malec, MD, MSc; Senior Medical Director, Versiti Comprehensive Center for Bleeding Disorders

March 15, 2025

7:00 AM - 8:00 AM - Explore a new treatment option for your patients with hemophilia with inhibitors

Sponsored by Novo Nordisk, Inc.

Hemophilia is a rare, lifelong bleeding disorder that requires ongoing care. Replacement therapy with clotting factor concentrates is the most common treatment for people with hemophilia A or hemophilia B. However, patients may develop alloantibodies, or inhibitors, that make factor replacement therapy ineffective. This is one of the most serious complications of treatment for patients with hemophilia. While there have been advances in the treatment options for people with hemophilia A with inhibitors, there remains a need for additional prophylactic non-factor therapy options, especially for people with hemophilia B with inhibitors. This program will provide information on a new prophylactic treatment option for people with hemophilia A and hemophilia B with inhibitors and share results from the clinical trial.

Speaker: Amy Shapiro, MD; Medical Director and CEO, Indiana Hemophilia and Thrombosis Center

7:00 AM - 8:00 AM -Real-World Experience With Gene Therapy for Adults with Hemophilia B: An Expert Panel Presentation

Sponsored by CSL Behring

In 2022, the FDA approved the first-ever gene therapy for adults with hemophilia B. Join us for an engaging panel presentation and discussion featuring Stephanie Ambrose, DO, and Aimee Foord, DO, as they highlight long-term (4-year) data and share their real-world experience with the gene therapy. Continuing education credits will not be offered for this program.

Speakers: Vidhi Desai, MD; Senior Medical Director, Coagulation, CSL Behring | Stephanie Phillips Ambrose, DO; Medical Director, South Carolina Hemostasis and Thrombosis Center Section Chief, Pediatric Nonmalignant Hematology, Prisma Health; Aimee Foord, DO; Director, Bleeding and Clotting Clinics, Attending Physician Pediatric Hematology Oncology, Cure 4 The Kids Foundation to your page